Cefpodoxime

From Infogalactic: the planetary knowledge core
Jump to: navigation, search
Cefpodoxime
Cefpodoxime.svg
Systematic (IUPAC) name
(6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyimino-acetyl]amino}-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Clinical data
Trade names Generic (formerly Vantin)
AHFS/Drugs.com monograph
MedlinePlus a698024
Pregnancy
category
  • AU: B1
  • US: B (No risk in non-human studies)
Legal status
Routes of
administration		 Oral
Pharmacokinetic data
Bioavailability 50%
Protein binding 21% to 29%
Metabolism Negligible. Cefpodoxime proxetil is metabolized to cefpodoxime by the liver
Biological half-life 2 hours
Excretion Renal, unchanged
Identifiers
CAS Number 82619-04-3 YesY
ATC code J01DD13 (WHO)
PubChem CID: 6335986
DrugBank DB01416 N
ChemSpider 4891496 YesY
UNII 7R4F94TVGY N
KEGG D07650 YesY
ChEBI CHEBI:3504 N
ChEMBL CHEMBL1672 YesY
Chemical data
Formula C15H17N5O6S2
Molecular mass 427.458 g/mol
  • O=C2N1/C(=C(\CS[C@@H]1[C@@H]2NC(=O)C(=N\OC)/c3nc(sc3)N)COC)C(=O)O
  • InChI=1S/C15H17N5O6S2/c1-25-3-6-4-27-13-9(12(22)20(13)10(6)14(23)24)18-11(21)8(19-26-2)7-5-28-15(16)17-7/h5,9,13H,3-4H2,1-2H3,(H2,16,17)(H,18,21)(H,23,24)/b19-8-/t9-,13-/m1/s1 YesY
  • Key:WYUSVOMTXWRGEK-HBWVYFAYSA-N YesY
 NYesY (what is this?)  (verify)

Cefpodoxime is an oral, third-generation cephalosporin antibiotic. It is active against most Gram-positive and Gram-negative organisms. Notable exceptions include Pseudomonas aeruginosa, Enterococcus, and Bacteroides fragilis. Currently, it is only marketed as generic preparations in the USA, according to the FDA Orange Book. It is commonly used to treat acute otitis media, pharyngitis, sinusitis, and gonorrhea. It also finds use as oral continuation therapy when intravenous cephalosporins (such as ceftriaxone) are no longer necessary for continued treatment.

Pfizer, the parent company of Pharmacia & Upjohn, markets cefpodoxime proxetil under the trade name C-Doxim for veterinary use. The dose range in dogs is 5–10 mg/kg body weight, administered orally, once a day.

Finecure, India markets the products under trade name Cefpo.[1]

Cefpodoxime inhibits cell wall synthesis by inhibiting the final transpeptidation step of peptidoglycan synthesis in cell walls. It has well established pharmacokinetic profile with absorption of 50%. It is indicated in community acquired pneumonia, uncomplicated skin and skin structure infections, and uncomplicated urinary tract infections.

Structural formula of cefpodoxime proxetil

Spectrum of bacterial susceptibility and resistance

Cefpodoxime has been used to fight pathogenic bacteria responsible for causing gonorrhoea, tonsillitis, pneumonia, and bronchitis. Representative pathogenic genera include Streptococcus, Haemophilus, and Neisseria. The following represents MIC susceptibility data for a few medically significant microorganisms.

  • Haemophilus influenzae: ≤0.03 - 1 μg/ml
  • Neisseria gonorrhoeae: 0.004 - 0.06 μg/ml
  • Streptococcus pyogenes: ≤0.004 - 2 μg/ml

[2]

Brand Name

Brand Name: Toraxim (Delta Pharma Ltd. Bangladesh)

Marketed Also As : Orelox By SanoFi-Aventis Pharma[3]

References

  1. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  2. ↑ http://www.toku-e.com/Assets/MIC/Cefpodoxime%20Free%20acid.pdf
  3. ↑ Lua error in package.lua at line 80: module 'strict' not found.

External links

Retrieved from "https://infogalactic.com/w/index.php?title=Cefpodoxime&oldid=1647524"